微小RNA与人类免疫缺陷病毒1型感染:生物标记及抗病毒治疗  

miRNAs and human immunodeficiency virus type 1 infection:biomarkers and antiviral therapy

作　　者：廖启彬 朱凌燕[1,2] 张晓燕[1,2] 徐建青[1,2] 

机构地区：[1]上海市(复旦大学附属)公共卫生临床中心,上海201508 [2]复旦大学生物医学研究院,上海200032

出　　处：《微生物与感染》2015年第5期318-323,共6页Journal of Microbes and Infections

基　　金："十二五"国家科技重大专项(2012ZX10001006-003)

摘　　要：微小RNA（miRNA）是一类非编码小RNA，长度为18-25个核苷酸，可结合mRNA的3’非翻译区，发挥着重要的转录后调控作用。miRNA涉及人类多种疾病的形成，因此迅速成为疾病诊断、预后评价的新一代生物标记及新型治疗靶点。在人类免疫缺陷病毒（HIV）／获得性免疫缺陷综合征（AIDS）的疾病进展过程中，宿主miRNA可能通过直接干预病毒复制或免疫应答而影响宿主的临床转归。本文主要综述宿主miRNA作为HIV-1感染疾病进展预测标记和抗病毒治疗潜在靶标的研究进展。microRNA （miRNA） is a class of small non-coding RNA with the length of 18-25 nucleotides, which plays an important role in regulating posttranscriptional level gene expression through binding to 3＇- untranslated region （IATR） of mRNA. Given its involvement in the development of various human diseases, miRNAs are emerging as a new generation biomarkers for diagnosis and prognosis, as well as novel therapeutic targets. The disease progression of human immunodeficiency virus （HIV）/acquired immunodeficiency syndrome （AIDS） might be modified by miRNA through the regulation of viral replication or host immune responses induced by HIV-1 infection. Here, the progresses on host miRNAs as potential biomarkers for disease progression in HIV-1 infection, as well as potential targets for antiretroviral therapy are reviewed in the present paper.

关 键 词：人类免疫缺陷病毒1型 微小RNA 疾病进展 治疗 

分 类 号：R512.91[医药卫生—内科学]